Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MissionAD1: Elenbecestat in Early Alzheimer's Disease
NCT02956486Phase 3Terminated
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2016
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of elenbecestat in Alzheimer's disease (AD), sponsored by Eisai Co., Ltd.. Started Oct 2016; status: terminated.
02
Drugs
elenbecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02956486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956486.